- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05513586
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)
The main aim of the study is to check side effect from the study treatment with TAK-771 in long term.
Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years.
There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Takeda Contact
- Phone Number: +1-877-825-3327
- Email: medinfoUS@takeda.com
Study Locations
-
-
-
Fukuoka, Japan
- Kyushu University Hospital
-
Gifu, Japan
- Gifu University Hospital
-
Hiroshima, Japan
- Hiroshima University Hospital
-
Saitama, Japan
- Saitama Prefectual Children's Medical Center
-
Shizuoka, Japan
- Shizuoka Childrens Hospital
-
-
Aichi
-
Nagoya, Aichi, Japan
- Nagoya University Hospital
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan
- Hospital of University of Occupational and Environmental Health
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
- Kanagawa Children's Medical Center
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
- Tokyo Medical Dental University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant have completed or is about to complete Study TAK-771-3004 (NCT05150340).
- Written and/or electronic informed consent is obtained from either the participant or the participant's legally authorized representative prior to any study-related procedures and study product administration. If a participant is <18 years of age, written and/or electronic informed consent should also be obtained from the participant's legally authorized representative in addition to written informed assent by a participant if appropriate.
- Participant is willing and able to comply with the requirements of the protocol.
Exclusion Criteria:
- Participant has developed a new serious medical condition during Study TAK-771-3004 such that the participant's safety or medical care would be impacted by participation in the study.
- Participant is willing to participate in other clinical trials.
Women of childbearing potential who meet any one of the following criteria:
- Participant presents with a positive pregnancy test.
- Participant does not agree to employ adequate birth-control measures (eg, intrauterine device, condom [for male partner], or birth-control pills) throughout the course of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAK-771
TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).
Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.
|
Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to 3 years
|
TEAEs are defined as AEs with onset after date-time of first dose of investigational drug or medical conditions present prior to the start of investigational drug but increased in severity or relationship after date-time of first dose of investigational drug.
|
Up to 3 years
|
Percentage of Participants who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160 and who Develop Neutralizing Antibodies to rHuPH20
Time Frame: Up to 3 years
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-771-3005
- jRCT2041220059 (Registry Identifier: jRCT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immunodeficiency Diseases (PID)
-
CSL BehringCompletedPrimary Immunodeficiency (PID)Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
-
ShireCompleted
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
Baxalta now part of ShireCompleted
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
CSL LimitedCompleted
-
TakedaTakeda Development Center Americas, Inc.Not yet recruitingPrimary Immunodeficiency Diseases (PID)
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Japan
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Clinical Trials on TAK-771
-
TakedaCompletedPrimary Immunodeficiency Diseases (PID)Japan
-
TakedaActive, not recruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)Japan
-
WockhardtCompletedBioavailabilityUnited States
-
TakedaTerminatedAttention-Deficit/Hyperactivity DisorderUnited States
-
TakedaTerminatedCardiovascular Disease | Type 2 DiabetesUnited States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
-
TakedaCompletedHealthyUnited Kingdom
-
TakedaWithdrawn